40.74
Moonlake Immunotherapeutics stock is traded at $40.74, with a volume of 63,231.
It is down -2.25% in the last 24 hours and down -6.48% over the past month.
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.
See More
Previous Close:
$41.76
Open:
$41.75
24h Volume:
63,231
Relative Volume:
0.20
Market Cap:
$2.61B
Revenue:
-
Net Income/Loss:
$-80.77M
P/E Ratio:
-32.08
EPS:
-1.27
Net Cash Flow:
$-80.80M
1W Performance:
-0.34%
1M Performance:
-6.48%
6M Performance:
-11.85%
1Y Performance:
-19.84%
Moonlake Immunotherapeutics Stock (MLTX) Company Profile
Name
Moonlake Immunotherapeutics
Sector
Industry
Phone
41 41 510 8022
Address
DORFSTRASSE 29, ZUG
Compare MLTX with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
MLTX
Moonlake Immunotherapeutics
|
40.72 | 2.61B | 0 | -80.77M | -80.80M | -1.27 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
489.74 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
690.74 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
636.58 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
243.51 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
BNTX
Biontech Se Adr
|
113.14 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Moonlake Immunotherapeutics Stock (MLTX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jan-17-25 | Upgrade | Goldman | Neutral → Buy |
Nov-05-24 | Resumed | Wedbush | Outperform |
Aug-26-24 | Downgrade | Wolfe Research | Outperform → Peer Perform |
Jun-25-24 | Initiated | Oppenheimer | Outperform |
Apr-02-24 | Initiated | Goldman | Neutral |
Feb-15-24 | Initiated | Wolfe Research | Outperform |
Dec-08-23 | Initiated | Citigroup | Buy |
Nov-02-23 | Initiated | Stifel | Buy |
Sep-14-23 | Downgrade | Bryan Garnier | Buy → Neutral |
Aug-31-23 | Initiated | Needham | Buy |
Jun-15-23 | Initiated | Barclays | Equal Weight |
May-01-23 | Initiated | Guggenheim | Buy |
Mar-22-23 | Initiated | Wedbush | Outperform |
Mar-09-23 | Initiated | BTIG Research | Buy |
Feb-14-23 | Initiated | Cantor Fitzgerald | Overweight |
Feb-02-23 | Initiated | Bryan Garnier | Buy |
Nov-11-22 | Initiated | Jefferies | Buy |
Aug-25-22 | Initiated | SVB Leerink | Outperform |
Jul-21-22 | Initiated | H.C. Wainwright | Buy |
Jul-07-22 | Initiated | Cowen | Outperform |
View All
Moonlake Immunotherapeutics Stock (MLTX) Latest News
The Goldman Sachs Group Cuts MoonLake Immunotherapeutics (NASDAQ:MLTX) Price Target to $73.00 - Defense World
Brokers Offer Predictions for MLTX Q2 Earnings - MarketBeat
MoonLake Immunotherapeutics (MLTX) Projected to Post Earnings on Thursday - MarketBeat
(MLTX) Technical Pivots with Risk Controls - Stock Traders Daily
The Goldman Sachs Group Has Lowered Expectations for MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price - MarketBeat
MoonLake Immunotherapeutics' (MLTX) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Needham & Company LLC Increases MoonLake Immunotherapeutics (NASDAQ:MLTX) Price Target to $66.00 - MarketBeat
MoonLake Immunotherapeutics (NASDAQ:MLTX) Issues Earnings Results, Misses Expectations By $0.09 EPS - MarketBeat
MoonLake Immunotherapeutics: Buy Rating Backed by Promising SLK Data and Strong Financial Position - TipRanks
Buy Rating for MoonLake Immunotherapeutics Driven by Promising Clinical Programs and Market Potential - TipRanks
Moonlake Immunotherapeutics Faces Hurdles in Commercializing SLK Despite Potential Approvals - TipRanks
MoonLake Immunotherapeutics: Strong Buy Rating Amid Promising Phase 3 Trials and Robust Financial Position - TipRanks
Buy Rating for MoonLake Immunotherapeutics: Strong Financials and Promising Clinical Developments - TipRanks
MoonLake Immunotherapeutics: Promising Future with Strong Financial Position and Clinical Advancements - TipRanks
MoonLake Immunotherapeutics reports Q4 EPS (72c), consensus (59c) - TipRanks
MoonLake Immunotherapeutics Q4 Loss Widens -February 26, 2025 at 07:53 am EST - Marketscreener.com
Earnings Flash (MLTX) MoonLake Immunotherapeutics Posts Q4 Loss of $-0.72 a Share, vs. FactSet Est of $-0.59 Loss - Marketscreener.com
MoonLake Immunotherapeutics Reports Full Year 2024 Financial Results and Provides a Business Update - The Manila Times
MoonLake Immunotherapeutics SEC 10-K Report - TradingView
Is MoonLake Immunotherapeutics (MLTX) An Oversold Biotech Stock to Buy Now? - Insider Monkey
This MoonLake Immunotherapeutics Insider Reduced Their Stake By 50% - Simply Wall St
Why MoonLake Immunotherapeutics is the Dark Horse Pharma Stock to Watch in 2025 - DSA
MoonLake Immunotherapeutics (MLTX): the Most Oversold Pharma Stock to Buy According to Analysts - Insider Monkey
10 Oversold Pharma Stocks to Buy According to Analysts - Insider Monkey
Congress Asset Management Co. Raises Stock Position in MoonLake Immunotherapeutics (NASDAQ:MLTX) - MarketBeat
Goldman Sachs Thinks Mid-Cap Biotech MoonLake Could Soar Over 80%: Is Retail Watching Closely? - MSN
Rice Hall James & Associates LLC Raises Holdings in MoonLake Immunotherapeutics (NASDAQ:MLTX) - MarketBeat
Will MoonLake Immunotherapeutics Lead Healthcare Stocks’ Resurgence? - DSA
Why MoonLake Immunotherapeutics Could Be the Next Big Bet in Healthcare - MotoPaddock
MoonLake Immunotherapeutics (MLTX): Among the Most Oversold Healthcare Stocks to Buy Now - Insider Monkey
12 Most Oversold Healthcare Stocks to Buy Now - Insider Monkey
(MLTX) Proactive Strategies - Stock Traders Daily
What is Leerink Partnrs' Forecast for MLTX FY2025 Earnings? - MarketBeat
We're Hopeful That MoonLake Immunotherapeutics (NASDAQ:MLTX) Will Use Its Cash Wisely - Yahoo Finance
Leerink Partnrs Has Negative Outlook of MLTX FY2025 Earnings - Defense World
MoonLake Immunotherapeutics (NASDAQ:MLTX) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
JPMorgan Chase & Co. Has $62,000 Position in MoonLake Immunotherapeutics (NASDAQ:MLTX) - MarketBeat
(MLTX) Trading Report - Stock Traders Daily
MoonLake Immunotherapeutics (NASDAQ:MLTX) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
JPMorgan Chase & Co. Reduces Stock Holdings in MoonLake Immunotherapeutics (NASDAQ:MLTX) - Defense World
Swiss company MoonLake leverages Cambridge in transformative year - Business Weekly
When the Price of (MLTX) Talks, People Listen - Stock Traders Daily
Cantor Fitzgerald Estimates MLTX FY2025 Earnings - Defense World
Cantor Fitzgerald Weighs in on MLTX FY2025 Earnings - MarketBeat
MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Up 6.3%Still a Buy? - MarketBeat
Barclays PLC Purchases 5,229 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) - Defense World
Comparing Petros Pharmaceuticals (NASDAQ:PTPI) & MoonLake Immunotherapeutics (NASDAQ:MLTX) - Defense World
Goldman Sachs raises target price for dermatological drug maker MoonLake by 32% - Kursiv Media
Moonlake Immunotherapeutics Stock (MLTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Moonlake Immunotherapeutics Stock (MLTX) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Sturge Simon | Director |
Oct 04 '24 |
Sale |
53.72 |
171,000 |
9,186,120 |
171,980 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):